Periodic Reporting for period 1 - ExitAplasia (Reg-X310: new disruptive medicine for faster exit from aplasia afetr agressive chemotherapy of hematologic malignancies)
Reporting period: 2018-11-01 to 2019-04-30
These treatments induce “aplasia”: the bone marrow doesn’t produce cells for the bloodstream anymore; these cells are well known and crucial for life: red cells (oxygen transport), white cells (immune defense against infection, bacteria, viruses), and platelets (to prevent bleeding after injuries).
These patients can be very young and even child can be concerned.
This aplasia has to be transient: it is a very serious condition which leads to death if it lasts too long; after a few days, the patients usually recover from aplasia, but meanwhile, they can suffer from uncontrolled infection or life-threatening bleeding.
Thus, the longer is aplasia, the higher is the risk of death for the patients. And the patients who do not succeed in recover from aplasia die.
We invented a mean to shorten this aplasia, increase the rate and speed of recovery from it. We are currently designing new drugs to specifically shorten it and increase the chance of survival for these patients.
It would also strongly shorten the lenght and consistenly decrease the cost of hospitalization. Thus, the financial burden of the concerned diseases would also be significantly decreased.